MR4.5 Matters: giving Ph+ CML-CP patients the best chance of optimal outcomes
Make MR4.5 the treatment goal for improved patient outcomes1
Lower rate of progression1
With median follow-up of 3 years, assessment of progressions according to response level showed that no patients with confirmed MR4.5 progressed (n=1524)1
Number of patients who progressed after median observation times between 3.8 and 4.7 years1
Improved overall survival1
Patients who achieved MR4.5 (8-year OS advantage of 9% with CCyR [P=.047])1
Improved Overall Survival for Patients who Achieved MR4.51
CML, chronic myeloid leukemia; IS, International Scale; CCyR, complete cytogenetic response; MMR, major molecular response; MR4, BCR-ABLIS ≤ 0.01%; MR4.5, BCR-ABLIS ≤ 0.0032%; OS, overall survival; Ph+, Philadelphia chromosome-positive.
- Hehlmann R, et al. J Clin Oncol. 2014;32:415-423.